Vericel Corporation (formerly Aastrom Biosciences) is currently evaluating its autologous cellular therapies in late-stage U.S. clinical trials in the treatment of dilated cardiomyopathy (DCM). This critical disease is associated with significant morbidity and mortality and very limited treatment options
Location: United States, Massachusetts, Cambridge
Employees: 201-500
Phone: (617) 588-5555
Founded date: 1989
Investors 1
| Date | Name | Website |
| - | Ignite 500 | ignite500.... |
Mentions in press and media 3
| Date | Title | Description |
| 29.08.2025 | Engineered Skin Substitutes Edge Closer to Clinical Reality | Researchers are advancing lab-grown skin substitutes that could reshape treatment for burns and chronic wounds. A comprehensive overview of this progress, published in Nature Outlook: Skin, highlights how multilayer grafts are moving closer... |
| 13.09.2018 | Vericel brings cell therapy to knee patients | “The issue with cartilage is that it doesn’t have any intrinsic healing properties,” said Vericel President and CEO Nick Colangelo in a phone interview. “Once you have a cartilage injury that’s left untreated, it leads to pain and dysfuncti... |
| - | Vericel brings cell therapy to knee patients | Last month, Vericel reported record second quarter revenues – the fifth consecutive time they have topped previous numbers. The Cambridge Massachusetts-based cell therapy company has two products on the market: Epicel to help burn patients ... |